Free Trial

Standard BioTools (NASDAQ:LAB) Trading Down 3.3% - Here's What Happened

Standard BioTools logo with Medical background

Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) traded down 3.3% during mid-day trading on Thursday . The stock traded as low as $1.33 and last traded at $1.33. 158,238 shares traded hands during trading, a decline of 92% from the average session volume of 1,947,274 shares. The stock had previously closed at $1.37.

Standard BioTools Trading Down 1.8%

The firm's 50-day moving average price is $1.11 and its 200-day moving average price is $1.29. The stock has a market capitalization of $510.86 million, a PE ratio of -3.84 and a beta of 1.54.

Institutional Trading of Standard BioTools

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LAB. Long Focus Capital Management LLC purchased a new stake in Standard BioTools in the 1st quarter worth about $7,236,000. Mirabella Financial Services LLP purchased a new stake in Standard BioTools in the 4th quarter worth about $5,478,000. Pacific Capital Partners Ltd purchased a new stake in Standard BioTools in the 1st quarter worth about $1,701,000. Royce & Associates LP raised its position in Standard BioTools by 136.8% in the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company's stock worth $2,547,000 after purchasing an additional 840,951 shares during the period. Finally, Nuveen LLC purchased a new stake in Standard BioTools in the 1st quarter worth about $862,000. 53.74% of the stock is owned by hedge funds and other institutional investors.

About Standard BioTools

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

Read More

Should You Invest $1,000 in Standard BioTools Right Now?

Before you consider Standard BioTools, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.

While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines